Ab Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science SA announces initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer
AB Science SA:Says it has initiated a phase 3 study to evaluate the safety and efficacy of masitinib in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC) in first relapse.Says this is a study to evaluate the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) for second-line treatment of patients with metastatic colorectal cancer.Says the study will measure overall survival as a primary efficacy criterion.Says one of the objectives of this phase 3 study in colorectal cancer will be to identify those subgroups that best respond to masitinib.
Latest Developments for Ab Science SA
- AB Science announces publication of results from randomized phase 2 study of masitinib
- AB Science proposes allocation of FY 2013 result and share repurchase program
- AB Science SA leaves SBF 120 Index and share price falls sharply-DJ
- AB Science SA Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis
Latest Key Developments in Pharmaceuticals
- Clinuvel Pharmaceuticals Ltd announces SCENESSE vitiligo study results
- Hangzhou Tianmushan Pharmaceutical Enterprise to sell entire stake in wholly owned subsidiary
- Aratana Therapeutics Inc announces full exercise of underwriters' option to purchase additional shares
- FDA approves Eli Lilly and Co's Trulicity (dulaglutide)
- Share this
- Digg this